Haem oxygenase-1 induction prevents glucocorticoid-induced osteoblast apoptosis through activation of extracellular signal–regulated kinase1/2 signalling pathway

Qiaoli Gu, Mimi Chen, Yu Zhang, Yingkang Huang, Huilin Yang**, Qin Shi*,**

Department of Orthopaedic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People’s Republic of China

Received 14 November 2018; received in revised form 4 March 2019; accepted 4 April 2019
Available online 28 April 2019

Abstract Background: High-dose glucocorticoid (GC) therapy always causes osteoporosis partly by inducing osteoblast apoptosis. However, the underlying mechanisms of GC-induced apoptosis remain elusive. Haem oxygenase-1 (HO-1) is a cytoprotective protein that rescues cells from H2O2 or high glucose–induced apoptosis. In bone metabolism, HO-1 also participates in osteoclast and osteoblast differentiation.

Objective: The present study aimed to investigate the protective role of HO-1 against GC-induced osteoblast apoptosis and to elucidate the underlying mechanism.

Methods: Mouse osteoblastic MC3T3-E1 cells were treated with dexamethasone (Dex) for 24 h in the presence or absence of cobalt (III) protoporphyrin IX chloride (CoPP, an inducer of HO-1). In some experiments, U0126 was added to the culture 1 h before CoPP treatment. The induction of apoptosis was determined by flow cytometry. Cell viability was evaluated using a cell counting kit-8 (CCK-8) assay. The expression levels of Bax and bcl-2 were measured by real-time polymerase chain reaction and Western blot. HO-1, extracellular signal–regulated kinase (ERK)-1/2 and pERK1/2 protein levels were measured by Western blot analysis.

Results: Dex promoted apoptosis and inhibited cell viability in MC3T3-E1 cells. In addition, Dex significantly increased Bax expression and reduced Bcl-2 expression. The expression of HO-1...
Introduction

Glucocorticoids (GCs) are effective agents used in treating cancer, autoimmune diseases and inflammatory disorders [1,2]. However, high-dose or long-term use of GCs is the primary cause of secondary osteoporosis because GCs exert direct effects on the skeletal system. GCs suppress bone formation and increase bone resorption, which finally lead to GC-induced osteoporosis (GIOP) [3,4]. Osteoporotic fractures may occur in 30–50% of patients receiving long-term GC administration [4]. Thus, there is a great need to clarify the pathogenesis of GIOP and develop effective therapeutic strategies.

Coordinated cycles of bone formation and resorption require an orchestrated interplay among osteoblasts, osteocytes and osteoclasts [5]. GCs can increase osteoclast generation and induce osteocyte apoptosis [6–8]. Osteoblasts are responsible for bone formation. The inhibition of bone formation is critical to the pathogenesis of GIOP. GCs significantly decrease the number of osteoblasts. On the one hand, GCs inhibit the production of new osteoblast precursors. On the other hand, GCs induce the apoptosis of mature osteoblasts [9–11]. Previous studies have reported that GCs can induce osteoblast apoptosis through triggering endoplasmic reticulum (ER) stress, inducing proapoptotic proteins or suppressing tissue inhibitor of metalloproteinase-1 [12–14]. However, the underlying mechanism of GC-induced osteoblast apoptosis has not been fully elucidated.

Haem oxygenase (HO) is the rate-limiting enzyme that degrades haem to biliverdin, carbon monoxide and free iron [15]. Three isoforms of HO (HO-1, HO-2 and HO-3) have been identified. HO-1 is a protective protein possessing anti-apoptotic, antiinflammatory and antioxidant effects [16–18]. HO-1 was also found to play a critical role in bone and fat metabolism [19–21]. Cobalt (III) protoporphyrin IX chloride (CoPP) is a potent HO-1 inducer. HO-1 induction by CoPP can protect HepG2 cells from cadmium-induced apoptosis in vitro [22]. The antiapoptotic effects of HO-1 induction may attribute to activating the extracellular signal–regulated kinase (ERK)/nuclear factor erythroid 2–related factor 2 (Nrf2) signalling pathway, inhibiting ER stress and c-Jun N-terminal kinase activation [18]. Although the cytoprotective effect of HO-1 has been extensively studied, the mechanisms of HO-1 against GC-induced osteoblast apoptosis remain unclear.

In the present study, we evaluate the effects of HO-1 on GC-induced osteoblast apoptosis and explored the underlying mechanisms. Dexamethasone (Dex), a synthetic GC, was used to induce osteoblast apoptosis. We present evidence that HO-1 induction by CoPP can prevent GC-induced osteoblast apoptosis. The antiapoptotic mechanism of HO-1 may involve the activation of ERK1/2 signalling pathway. Our findings indicate that HO-1 induction may be a useful therapeutic strategy for treating GIOP.

Materials and methods

Cell culture and treatment

Mouse osteoblastic MC3T3-E1 cells were grown in Dulbecco’s Modified Eagle’s Medium (high glucose; Gibco, Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% foetal bovine serum (Gibco, Thermo Fisher Scientific, Inc.), 100 U/ml penicillin (Sigma–Aldrich, St. Louis, MO, USA) and 100 μg/ml streptomycin (Sigma–Aldrich) in a humid incubator (Thermo Fisher Scientific, Inc.) with 5% CO2 at a temperature of 37°C. To induce apoptosis, MC3T3-E1 cells were treated with different concentrations of Dex (Sigma–Aldrich) for 24 h.

To induce HO-1 expression, CoPP (3 μM; Frontier Scientific, Logan, USA) was added to the culture 12 h before Dex treatment. In some experiments, U0126 (an inhibitor of ERK activation, 10 μM; Sigma–Aldrich) or tin protoporphyrin IX (an inhibitor of HO-1, SnPP, 20 μM; Cayman Chemical, Ann Arbor, MI, USA) was added to the culture 1 h before CoPP treatment.

Cell viability assay

Cell viability was assessed using a cell counting kit-8 (Dojindo Molecular Technologies, Inc., Kumamoto, Japan). Briefly, MC3T3-E1 cells (1 × 10^4) were seeded in 96-well plates, incubated overnight and treated with different concentrations of Dex for 24 h. Ten microlitres of cell counting kit-8 solution was added to the wells, and the cells were incubated for 2.5 h in the incubator. The absorbance values at 450 nm were measured using a Multi-Volume Spectrophotometer System (BioTek Epoch, Vermont, USA).
Apoptosis assay

Cell apoptosis was assessed by flow cytometry using an Annexin V Apoptosis Detection Kit (BD Biosciences, San Jose, CA, USA) according to the manufacturer’s instructions.

Reactive oxygen species measurement

MC3T3-E1 cells were cultured with Dex for 24 h and then washed three times with phosphate buffer solution solution. After this, cells were incubated with 10 μM dihydroethidine (Sigma–Aldrich) for 30 min and then harvested and washed three times with phosphate buffer solution solution. The fluorescence was determined by flow cytometry.

HO-1 activity measurement

HO-1 activity was measured as previously described with minor modification [23]. Cell lysates were added to the reaction mixture containing 30 μM haemin (Sigma–Aldrich), 2 mg/ml of rat liver cytosol, 1 mM MgCl2, 3 units of glucose-6-phosphatase dehydrogenase (Sigma–Aldrich), 1 mM glucose-6-phosphate (Solarbio Science & Technology, Beijing, China), 2 mM reduced nicotinamide adenine dinucleotide phosphate (Beiyotime Institute of Biotechnology, Jiangsu, China) and 0.1 M potassium phosphate buffer. The reaction was conducted at 37°C in the dark for 30 min and terminated by the addition of 1 ml of chloroform. The concentration of bilirubin was determined as the difference between the concentrations measured at 464 nm and 530 nm. The results were expressed as picomoles of bilirubin per milligram of protein.

Quantitative real-time polymerase chain reaction

Total RNA was extracted from MC3T3-E1 cells using TRIzol (Invitrogen Life Technologies, Paisley, UK) according to the manufacturer’s instructions and reverse transcribed. Real-time polymerase chain reaction was performed using SsoFast EvaGreen Supermix (Bio-Rad, Hercules, CA) and conducted with the Bio-Rad CFX96 (Bio-Rad). The primers for Bax were 5’-TGAAGACAGGGGCTTTTTG-3’ and 5’-AATTCCGCGAGAGCCTCG-3’. The primers for Bcl-2 were 5’-GTCGCTACCGTCTGACCTC-3’ and 5’-CAGACATGCACTTCCACG-3’. The primers for β-actin were 5’-GGCTGTATTC-CCTTCCATCG-3’ and 5’-CCATTTGGAACAATGCAATG-3’.

Western blot analysis

Protein extracts were resolved on sodium dodecyl sulfate–polyacrylamide gels and transferred to polyvinylidene difluoride membrane. The membrane was blocked with 5% freshly prepared milk-tris buffered saline Tween 20 for 2 h at room temperature and then incubated overnight at 4°C with antibodies specific for β-actin (Abcam, Cambridge, MA), HO-1, Bax, Bcl-2 (Beiyotime), ERK1/2 and pERK1/2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Signals were detected with horseradish peroxidase–labelled secondary antibodies by chemiluminescence labelling.

Statistical analysis

The results were presented as means ± standard deviation. The significance between two groups was determined using Student t test. One-way analyses of variance were used for multiple comparisons. p Values less than 0.05 were considered statistically significant. All statistical analyses were performed using the SPSS 16.0 software (SPSS, Chicago, IL, USA).

Results

Dex induces the apoptosis of MC3T3-E1 cells

Previous studies have indicated that osteoblasts are one of the main targets for GCs. The effect of Dex on the viability of osteoblasts was determined in mouse osteoblastic MC3T3-E1 cells. Significant declines in cell viability were observed after 24 h of treatment with 1 or 5 μM Dex as compared with the control (Fig. 1A). We then examined the cellular apoptosis using Annexin V-FITC/PI double staining method. The apoptotic rates of MC3T3-E1 cells were significantly increased after treatment with 1 or 5 μM Dex as compared with the control (Fig. 1B). We also examined the expression of apoptosis-related molecules. Dex treatment reduced Bcl-2 expression but increased Bax expression (Fig. 1C, D). All data demonstrated that Dex can promote apoptosis of mouse osteoblastic MC3T3-E1 cells.

CoPP induces HO-1 expression in MC3T3-E1 cells

CoPP is a potent HO-1 inducer. To test whether CoPP could induce HO-1 expression in MC3T3-E1 cells, we performed Western blotting to determine the protein level of HO-1. MC3T3-E1 cells were cultured under different concentrations of CoPP for 36 h. CoPP increased the expression of HO-1 in MC3T3-E1 cells in a dose-dependent manner (Fig. 2A). Particularly, the incubation of MC3T3-E1 cells with 5 μM CoPP caused a significant decrease in cell viability. CoPP at the concentration of 3 μM did not affect the viability of MC3T3-E1 cells (Fig. 2B). Thus, we chose 3 μM as the optimal concentration of CoPP to induce HO-1 in MC3T3-E1 cells.

To test whether HO-1 is involved in Dex-induced apoptosis of MC3T3-E1 cells, we then examined the effect of Dex on HO-1 expression. The results showed that Dex treatment caused a significant decrease in HO-1 expression as compared with the control (Fig. 2C). However, CoPP preconditioning significantly increased HO-1 expression as compared with Dex-treated group (Fig. 2C).

In addition, flow cytometry results showed that Dex significantly increased reactive oxygen species (ROS) generation as compared with the control. CoPP preconditioning reduced ROS levels as compared with the Dex-treated group (Fig. 2D).

HO-1 induction prevents Dex-induced apoptosis of MC3T3-E1 cells

As expected, in the presence of Dex, cells pretreated with CoPP showed a significant decrease in the rate of apoptosis (Fig. 3A). However, the beneficial effects of CoPP were reversed by additional pretreatment with SnPP, a HO-1...
inhibitor (Fig. 3A). SnPP can suppress HO-1 activity. We then analyzed the activity of HO-1 in MC3T3-E1 cells. As shown in Fig. 3B, Dex showed a tendency to reduce HO-1 activity in MC3T3-E1 cells. CoPP treatment increased HO-1 activity significantly as compared with the Dex-treated group. The effects of CoPP were reversed by additional pretreatment with SnPP. We further assessed the mRNA expression levels of Bax and Bcl-2. Dex increased Bax

Figure 1  The effects of Dex on the apoptosis of MC3T3-E1 cells. Mouse osteoblast MC3T3-E1 cells were cultured with indicated concentrations of Dex for 24 h. (A) Cell viability was measured using a CCK-8 kit. (B) Cell apoptosis was measured by flow cytometry. (C) The expressions of Bax and Bcl-2 were analyzed by real-time PCR. (D) The expressions of Bax and Bcl-2 were analyzed by Western blot. Data were represented as means ± SD of three individual experiments. *p < 0.05, **p < 0.01.

Dex = dexamethasone; PCR = polymerase chain reaction; SD = standard deviation; CCK-8 = cell counting kit-8.
expression and inhibited Bcl-2 expression in MC3T3-E1 cells. CoPP treatment negated the effects of Dex on Bax and Bcl-2 expression. The effects of CoPP were also reversed by additional pretreatment with SnPP (Fig. 3C). These results demonstrate that HO-1 induction by CoPP protects MC3T3-E1 cells against Dex-induced apoptosis.

Figure 2 The effects of CoPP on HO-1 expression in MC3T3-E1 cells. (A) Mouse osteoblast MC3T3-E1 cells were cultured with indicated concentrations of CoPP for 36 h. Western blot and quantitative analysis were performed to detect the expression of HO-1. (B) Cell viability was measured using a CCK-8 kit. (C) CoPP was added 12 h before Dex treatment. The expression of HO-1 was measured by Western blot 24 h after Dex treatment. (D) The expression of ROS was measured by flow cytometry. Data were represented as means ± SD of three individual experiments. *p < 0.05, **p < 0.01.

CoPP = cobalt (III) protoporphyrin IX chloride; Dex = dexamethasone; HO-1 = haem oxygenase-1; ROS = reactive oxygen species; SD = standard deviation; CCK-8 = cell counting kit-8.
HO-1 induction prevents Dex-induced apoptosis through ERK1/2 signalling

ERK pathway has been reported to participate in cell survival. To further elucidate the mechanism involved in the antiapoptotic effect of HO-1, we examined the activation of ERK pathway in MC3T3-E1 cells. As shown in Fig. 4A, Dex inhibited the phosphorylation of ERK1/2 but did not affect total ERK1/2 expression. CoPP treatment restored the phosphorylation of ERK1/2. U0126, an inhibitor of ERK activation, significantly inhibited the phosphorylation of ERK1/2. Moreover, CoPP-induced HO-1 expression was also...
reduced by U0126 (Fig. 4A). Flow cytometry analysis showed that U0126 abrogated the antiapoptotic effect of CoPP (Fig. 4B). These results indicate that HO-1 induction may alleviate Dex-induced apoptosis through the activation of ERK1/2 signalling pathway.

Discussion

GIOP is the most prevalent drug-induced osteoporosis, characterized by reduced bone formation and increased bone resorption. Increased osteoblast apoptosis is thought to be one of the main mechanisms that account for the disorder of bone metabolism. In the present study, we investigated the role of HO-1 in Dex-induced osteoblast apoptosis. We provide evidence that HO-1 induction by CoPP protects mouse osteoblasts against Dex-induced apoptosis through the activation of ERK1/2 signalling pathways.

Dex has been shown to induce apoptosis in osteoblastic cell lines (MC3T3-E1, UAMS-32 cell) [24,25]. Consistent with previous reports, we find high-dose Dex (1 or 5 μM) can induce apoptosis of MC3T3-E1 cells within 24 h as evidenced by Annexin V/PI staining. This was also confirmed by the
expression of apoptosis-related molecules. Dex treatment significantly increased bax expression while reduced bcl-2 expression. The proliferation of MC3T3-E1 cells was also reduced after Dex treatment. Although osteoblast apoptosis is commonly accepted as a key player in the pathogenesis of GIOP, the underlying mechanism remains poorly understood. Previous studies have shown that Dex induces osteoblast apoptosis by increasing E4BP4 expression or ER stress [26–28]. Autophagy activation also participates in Dex-induced apoptosis [28]. In the present study, we find that Dex significantly reduced HO-1 expression after incubation for 24 h with MC3T3-E1 cells. HO-1 is a stress-responsive enzyme that exerts potent cytoprotective effects in a wide range of cells and disease models. HO-1 deficiency results in increased apoptotic cells in mouse placentas [29]. Carbon monoxide, one of the by-products of HO-1, attenuates tumor necrosis factor-alpha–induced apoptosis of osteoblasts [30]. Based on previous studies, our findings suggest that HO-1 may participate in Dex-induced apoptosis of osteoblasts. Consistent with our results, Singh and Haldar [31] also observed that Dex represses HO-1 expression in peripheral blood mononuclear cells. However, Han et al. [32] have reported that Dex increases HO-1 expression after incubation for 6 h with MC3T3-E1 cells. The difference may be caused by different culture conditions. HO-1 is responsible for ROS scavenging [33]. HO-1 deficiency results in increased ROS levels in vascular adiopose precursor cells [34]. ROS induction leads to oxidative stress, a process that alters bone metabolism and contributes to the pathogenesis of osteoporosis [35]. As expected, we find a concomitant increase of ROS levels in MC3T3-E1 cells treated with Dex. Previous studies have reported that ROS is responsible for Dex- or homocysteine-induced apoptosis of osteoblasts [24,36]. This result provides further evidence that HO-1 is involved in Dex-induced apoptosis of MC3T3-E1 cells.

CoPP is a metalloprotoporphyrin used as a powerful inducer of HO-1. HO-1 induction by CoPP can protect astroglia against manganese-induced apoptosis or attenuate hepatocyte apoptosis. In the skeletal system, CoPP-induced HO-1 can protect osteoarthritis osteoblasts from senescence. In the present study, we find that 3 μM CoPP significantly induced HO-1 expression in MC3T3-E1 cells without affecting their apoptosis. Most importantly, preconditioning cells with CoPP for 12 h significantly inhibited Dex-induced apoptosis. The protective effects of CoPP can be reversed by SnPP, an inhibitor of HO-1. Moreover, HO-1 induction by CoPP significantly inhibited Bax expression and increased Bcl-2 expression, which further confirmed that HO-1 induction attenuates Dex-induced apoptosis. Our data indicate a therapeutic potential for HO-1 against Dex-induced apoptosis of osteoblasts.

We also find that the antiapoptotic effects of HO-1 induction were associated with the activation of ERK1/2. The ERK1/2 pathway regulates cell apoptosis, proliferation, autophagy and differentiation. Previous studies have reported that ERK activation can attenuate osteoblast apoptosis induced by Dex or 17β-estradiol [37,38]. In the present study, using U0126, an inhibitor of ERK activation, we find that inhibition of ERK activation significantly abrogated the protective effect of CoPP against Dex-induced apoptosis. Moreover, inhibition of ERK activation also reduced the expression of HO-1 in MC3T3-E1 cells. These results suggest that CoPP triggers the activation of ERK1/2 pathways, which induces an antiapoptotic effect in osteoblasts. Previous studies have shown that ERK kinase can phosphorylate Bad or Nrf2 [39,40]. Bad is a Bcl-2 family protein, and its phosphorylation can prevent apoptosis. Nrf2 is a key transcription factor that mediates antioxidant and antiinflammatory responses. ERK/Nrf2 signalling pathway plays an important role in CoPP-induced antiapoptotic response. However, identifying the downstream target of ERK needs more investigation.

**Conclusion**

In summary, we find that preconditioning of MC3T3-E1 cells with CoPP alleviates Dex-induced apoptosis through activation of ERK1/2 signalling. These results suggest that HO-1 participates in Dex-induced osteoblast apoptosis. HO-1 induction may be a promising therapeutic strategy against GC-induced osteoporosis.

**Conflict of interest**

The authors declare no conflict of interest.

**Acknowledgement**

This work was supported by the National Natural Science Foundation of China Grant 81301341, 81772313.

**References**

[1] Güler-Yuksel M, Hoes JN, Bulklnk IEM, Lems WF. Glucocorticoids, inflammation and bone. Calcif Tissue Int 2018;102(5):592–606.

[2] Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: a comprehensive review: a review of glucocorticoid pharmacology and bone health. J Am Acad Dermatol 2017;76(1):1–9.

[3] Zhang X, Chen K, Wei B, Liu X, Lei Z, Bai X. Ginsenosides Rg3 attenuates glucocorticoid-induced osteoporosis through regulating BMP-2/BMPR1A/Runx2 signaling pathway. Chem Biol Interact 2016;256:188–97.

[4] Canalis E, Mazzotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007;18(10):1319–28.

[5] Suen PK, Qin L. Sclerostin, an emerging therapeutic target for treating osteoporosis and osteoporotic fracture: a general review. J Orthop Translat 2015;4:1–13.

[6] Weinstein RS, Wan C, Liu Q, Wang Y, Almeida M, O’Brien CA, et al. Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice. Aging Cell 2010;9(2):147–61.

[7] Seeman E, Delmas PD. Bone quality—the material and structural basis of bone strength and fragility. N Engl J Med 2006;354(21):2250–61.

[8] Gao J, Cheng TS, Qin A, Pavlos NJ, Wang T, Song K, et al. Glucocorticoid impairs cell–cell communication by autophagy-mediated degradation of connexin 43 in osteocytes. Oncotarget 2016;7(19):26966–78.

[9] Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts...
and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998;102(2):274–82.

[10] Weinstein RS. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am 2012;41(3):595–611.

[11] O’Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004;145(4):1835–41.

[12] Sato AY, Tu X, McAndrews KA, Plotkin LI, Bellido T. Prevention of glucocorticoid-induced apoptosis of osteoblasts and osteocytes by protecting against endoplasmic reticulum (ER) stress in vitro and in vivo in female mice. Bone 2015;73:60–8.

[13] Chua CC, Chua BH, Chen Z, Landy C, Hamdy RC. Dexamethasone induces caspase activation in murine osteoblastic MC3T3-E1 cells. Biochim Biophys Acta 2003;1642(1–2):79–85.

[14] Xie H, Tang LL, Luo XH, Wu XY, Wu XP, Zhou HD, et al. Suppressive effect of dexamethasone on TIMP-1 production involves murine osteoblastic MC3T3-E1 cell apoptosis. Amino Acids 2010;38(4):1145–53.

[15] Maines MD. Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J 1998;2(10):2557–68.

[16] Thorenz A, Derlin K, Schroder C, Dressler L, Vijayan V, Xie H, Tang LL, Luo XH, Wu XY, Wu XP, Zhou HD, et al. Suppressive effect of dexamethasone on TIMP-1 production involves murine osteoblastic MC3T3-E1 cell apoptosis. Amino Acids 2010;38(4):1145–53.

[17] Sherif IO. The effect of natural antioxidants in cyclophosphamide-induced hepatotoxicity: role of Nrf2/HO-1 pathway. Int Immunopharmacol 2018;61:29–36.

[18] Maamoun H, Zachariah M, McVey JH, Green FR, Agouni A. Heme oxygenase (HO)-1 induction prevents endoplasmic reticulum stress-mediated endothelial cell death and impaired angiogenic capacity. Biochem Pharmacol 2017;127:46–59.

[19] Liu X, Ji C, Xu L, Yu T, Dong C, Luo J. Hmxox1 promotes osteogenic differentiation at the expense of reduced adipogenic differentiation induced by BMP9 in C3H10T1/2 cells. J Cell Biochem 2018;119(7):5503–16.

[20] Barbagallo I, Vanella A, Peterson SJ, Kim DH, Tibullo D, Giallongo C, et al. Overexpression of heme oxygenase-1 increases human osteoblast stem cell differentiation. J Bone Miner Metab 2010;28(3):276–88.

[21] Kim DH, Liu J, Bhat S, Benedict G, Lecka-Czernik B, Peterson SJ, et al. Peroxisome proliferator-activated receptor delta agonist attenuates nicotine suppression effect on human mesenchymal stem cell-derived osteogenesis and involves increased expression of heme oxygenase-1. J Bone Miner Metab 2013;31(1):44–52.

[22] Lawal AO, Marnewick JL, Ellis EM. Heme oxygenase-1 attenuates cadmium-induced mitochondrial-caspase 3-dependent apoptosis in human hepatoma cell line. BMC Pharmacol Toxicol 2015;16:41.

[23] Oh GS, Pae HO, Lee BS, Kim BN, Kim JM, Kim HR, et al. Hydrogen sulfide inhibits nitric oxide production and nuclear factor-kappaB via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide. Free Radic Biol Med 2006;41(1):106–19.

[24] Almeida M, Han L, Ambrogini E, Weinstein R, Manolagas SC. Glucocorticoids and tumor necrosis factor alpha increase oxidative stress and suppress Wnt protein signaling in osteoblasts. J Biol Chem 2011;286(52):44326–35.

[25] Liu S, Fang T, Yang L, Chen Z, Mu S, Fu Q. Gastrodin protects MC3T3-E1 osteoblasts from dexamethasone-induced cellular dysfunction and promotes bone formation via induction of the Nrf2 signaling pathway. Int J Mol Med 2018;41(4):2059–69.

[26] Chen F, Zhang L, OuYang Y, Guan H, Liu Q, Ni B. Glucocorticoid induced osteoblast apoptosis by increasing E4BP4 expression via up-regulation of Bim. Calcif Tissue Int 2014;94(6):640–7.

[27] Yang J, Wu Q, Lv J, Nie H, 4-Phenyl butyric acid prevents glucocorticoid-induced osteoblast apoptosis by attenuating endoplasmic reticulum stress. J Bone Miner Metab 2017;35(4):366–74.

[28] Liu W, Zhao Z, Na Y, Meng C, Wang J, Bai R. Dexamethasone-induced production of reactive oxygen species promotes apoptosis via endoplasmic reticulum stress and autophagy in MC3T3-E1 cells. Int J Mol Med 2018;41(4):2028–36.

[29] Zhao H, Wong RJ, Kalish FS, Nayak NR, Stevenson DK. Effect of heme oxygenase-1 deficiency on placental development. Placenta 2009;30(10):861–8.

[30] Chae HJ, Chihn HY, Lee GY, Park HR, Yang SK, Chung HT, et al. Carbon monoxide and nitric oxide protect against tumor necrosis factor-alpha-induced apoptosis in osteoblasts: HO-1 is necessary to mediate the protection. Clin Chim Acta 2006;365(1–2):270–8.

[31] Singh AK, Haldar C. Melatonin modulates glucocorticoid receptor mediated inhibition of antioxidant response and apoptosis in peripheral blood mononuclear cells. Mol Cell Endocrinol 2016;436:59–67.

[32] Han D, Gao J, Gu X, Hengstler JG, Zhang L, Shahid M, et al. P21(Waf1/Cip1) depletion promotes dexamethasone-induced apoptosis in osteoblastic MC3T3-E1 cells by inhibiting the Nrf2/HO-1 pathway. Arch Toxicol 2018;92(2):679–92.

[33] Loboda A, Damulewicz M, Pyza E, Jozkowicz A, Dulak J. Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism. Cell Mol Life Sci 2016;73(17):3221–47.

[34] Wagner G, Lindroos-Christensen J, Einwallner E, Husa J, Zapf TC, Lipp K, et al. HO-1 inhibits preadipocyte proliferation and differentiation at the onset of obesity via ROS dependent activation of Akt2. Sci Rep 2017;7:40881.

[35] Luo S, Yang Y, Chen J, Zhong Z, Huang H, Zhang J, et al. Tanshinol stimulates bone formation and attenuates dexamethasone-induced inhibition of osteogenesis. J Orthop Translat 2015;4:35–45.

[36] Kanazawa I, Tomita T, Miyazaki S, Ozawa E, Yamamoto LA, Sugimoto T. Bazedoxifene ameliorates homocysteine-induced apoptosis and accumulation of advanced glycation end products by reducing oxidative stress in MC3T3-E1 cells. Calcif Tissue Int 2017;100(3):286–97.

[37] Kousneti S, Bellido T, Plotkin LI, O’Brien CA, Bodenner DL, Han L, et al. Nongenotoxic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 2001;104(5):719–30.

[38] Liu Y, Porta A, Peng X, Gengaro K, Cunningham EB, Li H, et al. Prevention of glucocorticoid-induced apoptosis in osteocytes and osteoblasts by calbindin-D28K. J Bone Miner Res 2004;19(3):479–90.

[39] Scheid MP, Schubert KM, Duronio V. Regulation of bad phosphorylation and association with Bcl-x(L) by the MAPK/Erk kinase. J Biol Chem 1999;274(43):31108–13.

[40] Zipper LM, Mulcahy RT. Erk activation is required for Nrf2 transcriptional activity. Cell 2001;104(5):719–30.